On Tuesday, Novartis AG and GlaxoSmithKline PLC unveiled a series of transactions worth more than $20 billion that fundamentally transform both companies, more tightly focusing Novartis's scope without significantly crimping its revenue, while turning Glaxo into a vaccines-and-consumer-drug powerhouse.

The deals, announced before trading opened in Europe, follow news that activist...